Kornimate/medical-research-clean huggingface dataset:
effects of gw679769 on bladder nerve function and symptoms of overactive bladder in spinal cord injury patients

Conditions: Incontinence, Urinary and Urinary Bladder, Overactive; Overactive Bladder

Summary: this is a two-part study in which part a will assess the effects of gw679769 after 1 dose on the function of the nerves that supply the bladder. the technique for measuring the nerves function is called neurometry. part b will assess the effect of repeat doses of gw679769 on the bladder nerve function. part b will also assess the effects of the drug on overactive bladder symptoms using a three-day patient diary.

a randomized, double-blind, placebo-controlled study to evaluate the effects of gw679769 on current perception threshold (cpt) following a single 150 mg dose (part a) and to evaluate the effect of cpt and symptoms of overactive bladder following 28 days of repeat dosing with 120 mg gw679769 administered once daily (part b) in patients with neurogenic bladder due to incomplete spinal cord injury

Eligibility criteria:
inclusion criteria: * spinal cord injury patients with overactive bladder symptoms including urge incontinence, urgency, frequency and night-time urination but without bladder related pain. * the injury must be above s1-3 exclusion criteria: * spinal cord injury suffered within 6 months. * history of interstitial cystitis, radiation cystitis, pelvic irradiation, or myocardial infarction with 1 year prior to screening. * pregnant or nursing females. * patients who have had hypersensitivity to lidocaine. * patients who are taking oral corticosteroids. * patients with active peptic ulcer disease (pud) and/or history of pud of an unknown etiology.

Keywords: spinal cord injury urgency overactive bladder neurogenic neurometry frequency urge incontinence
a study of niaspan on endothelium-dependent and endothelium-independent vascular reactivity (0000-093)

Conditions: Dyslipidemia

Summary: a study to evaluate the inter- and intra subject variabilities of flow-mediated dilation (fmd) of brachial artery and nitroglycerin (gtn) induced dilation of brachial artery.


Eligibility criteria:
inclusion criteria: * female subjects of reproductive potential test negative for pregnancy and agree to use appropriate methods of contraception throughout the study * subject is in good health (other than history of high cholesterol) * subject is a non-smoker exclusion criteria: * subject has a history of stroke, seizures or major neurological disorder * subject has a history of cancer * subject is unable to refrain from or anticipates the use any prescription or non-prescription drugs * subjects consumes excessive amounts of alcohol or caffeine
the safety and effectiveness of intravenous anidulafungin as a treatment for patients with invasive candidiasis.

Conditions: Candidiasis

Summary: anidulafungin may be effective for the treatment of invasive candida infections. the purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of united states patients with invasive candidiasis.


Eligibility criteria:
inclusion criteria: * positive culture plus at least one clinical sign and symptom consistent with invasive candidiasis preferably within 96 hours of the proposed first dose of study drug * life expectancy: greater than 72 hours exclusion criteria: * pregnant females * treatment with other investigational drug(s) within 4 weeks * hypersensitivity to anidulafungin or echinocandin therapy * hypersensitivity to tween 80 (polysorbate 80) or tartaric acid

Keywords: anidulafungin candidemia invasive candidiasis
linagliptin in schizophrenia patients

Conditions: Schizophrenia

Summary: approximately one third of patients with schizophrenia show a poor response to standard treatment with antipsychotic medications. this treatment resistant group of patients represents a major challenge in everyday psychiatry, and consumes a disproportionate amount of time from the clinicians, resulting in considerable costs to the society and government. anecdotal evidence suggests that the enzyme dipeptidyl peptidase iv (dppiv) may be altered in patients with schizophrenia, with a higher level dppiv enzyme activity being noted. we postulate that this may play a role in the neuropathology of schizophrenia patients and by inhibiting the dppiv enzyme activity with a dppiv inhibitor such as linagliptin, we will be able to improve and even ameliorate the symptoms of schizophrenic patients. however, until now there have yet any studies on the potential of these inhibitors in schizophrenia patients. a pilot study is thus proposed to evaluate the potential of the dppiv inhibitor, linagliptin as an adjunct in schizophrenia patients who are non-responsive to treatment, which will establish the feasibility of a larger trial.


Eligibility criteria:
inclusion criteria: * 18 years of age and above * diagnosis of schizophrenia. * clinically stable antipsychotic regimen for the last 3 months * a total score of 80 or greater at baseline on the positive and negative syndrome scale * competent and willing to provide written, informed consent exclusion criteria: * history of substance dependence within the past 2 months * existing relevant physical health problems: such as uncontrolled cardiovascular disease and impaired liver/ renal function * history of diabetes * history of hepatic or biliary diseases / biliary obstruction * a serious suicide/homicide risk in the opinion of the investigator * known allergy to linagliptin
families and schools for health

Conditions: Overweight; Pediatric Obesity

Summary: the purpose of the study is to test the effectiveness of a child obesity intervention with multiple components targeting nutrition and/or psycho-social factors in children, their parents, and their classmates. the specific aims of the study are to (1) determine the effectiveness of two family-level interventions for improving child outcomes (unhealthy eating, low activity, and overweight); (2) determine the extent to which adding a family dynamics component enhances the effectiveness of a family lifestyle intervention and improves the child outcomes listed above; and (3) determine the extent to which a peer-level intervention improves the effectiveness of two family-level interventions among overweight children.

the families and schools for health (fish) project evaluates a psychosocial intervention that targets the family and peer contexts of overweight children. 23 rural schools were identified for participation (schools within a 90-mile radius of the pi's campus were targeted) and each was assigned to one of five intervention conditions using stratified random sampling, with stratification based on proximity to each other (to avoid spill-over effects) and proportion of native american indian students. a community sample of 1186 1st grade children, their families, and their teachers were successfully recruited. anthropometric assessments were conducted with the 1186 children. those who were not at control schools were invited to participate in the intervention. 541 children qualified for the intervention (i.e., had bmi% \> 75%), including 459 at intervention schools and 82 at control schools. intervention conditions were (1) a 12-week family food \& lifestyle intervention (fl), aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating; (2) a 12-week family food \& lifestyle and family dynamics intervention (fl+fd) that additionally targets dysfunctional family patterns such as high conflict, poor parent-child communication, and parental over-control or permissiveness; and (3) a peer group (pg) intervention conducted throughout one semester of the school year that includes a guidance-type curriculum sensitizing children to the importance of social inclusion of all children. thus, 5 treatment groups were evaluated in the intervention year and followed through 4th grade: fl, fl+fd, fl+pg, fl+fd+pg, and control. child psychosocial variables such as emotional eating, self-esteem, loneliness, and social withdrawal will be analyzed as mediators between family/peer contexts and child overweight.

Eligibility criteria:
inclusion criteria: * children with bmi% greater than or equal to 75% who were enrolled in first grade in participating schools. exclusion criteria: * children with bmi% \< 75%.

Keywords: child overweight child obesity family dynamics peer relationships family intervention school intervention parenting
project step ii: the effects of incentives and feedback on promoting walking within overweight and obese adults

Conditions: Physical Activity; Sedentary Lifestyle; Overweight and Obesity

Summary: this study will evaluate the main effects of daily vs. weekly feedback and contingent vs. non-contingent incentives for increasing walking behavior among overweight and obese adults.

approximately 68% of adults are overweight or obese, which is associated with increased risk for health conditions, including cardiovascular disease, type 2 diabetes, and cancer. these individuals are more often sedentary than the general population, which compounds the risk for these same conditions. while the benefits of engaging in physical activity are well-established, few individuals are able to successfully increase activity to recommended levels. existing intervention programs, often derived from theories such as social cognitive theory or related theories, have had limited success. behavioral economics offers a promising alternative, suggesting that engagement in any behavior is based on the maximizing utility and happiness (i.e., weighing the cost and benefit of the behavior). interventions based on this theory aim to increase the immediate benefit of engaging in physical activity, often using a financial incentive. this study will last for 8 weeks. all participants will have the use of a fitbit for ongoing self-monitoring and a personalized step-count goal designed to help increase daily steps. participants will receive feedback on reaching their goals either daily or weekly.

Eligibility criteria:
inclusion criteria: * 25 kg/m2 ≤ bmi ≤ 45 kg/m2 * age 18-70 * currently inactive (engages in less than 6,000 steps/day on at least 4 of 7 days per week or engaged in less than 10,000 steps /day on at least 5/7 days per week, confirmed by fitbit at baseline) * able to engage in moderate amount of walking * able to receive email/text messages from study staff exclusion criteria: * psychiatric conditions that would make it difficult to comply * medical conditions that would make it difficult to comply
effectiveness of sodium bicarbonate buffered anaesthetic solution on pain during injection

Conditions: Local Anesthesia

Summary: this study will test the effectiveness of addition of sodium bicarbonate as a buffering agent to the anaesthetic solution on minimizing the pain of injection and increasing the onset time and potency of the anaesthetic solution in children

27 healthy cooperative children will be enrolled in the study after taking their guardians' informed consent. the study design will be a split mouth design where each patient will be received buffered anaesthetic solution (8.4% sodium bicarbonate will be added to the anaesthetic solution in ratio 1:19) in one side and conventional anaesthetic solution (4% articaine hcl with 1:1000000 epinephrine) in the other side. the pain during injection for each patient in both sides will be then compared using objective and subjective methods. the onset time of the anaesthesia in both sides will also be compared for each patient using transcutaneous electric nerve stimulator device (tens) the results will be collected and mentioned.

Eligibility criteria:
inclusion criteria: * age range from 5 - 7 years. * children free of any systemic disease or special health care need (asa i). * no previous bad dental experience. * positive or definitely positive behaviour during preoperative assessments according to the frankl rating scale (score 3 or 4) * patients whom their lower primary molars bilaterally are indicated for pulpotomy. * patients whom their parents will give consent to participate. * patients who give multiple reliable responses while using the transcutaneous electric nerve stimulator device. exclusion criteria: * active sites of pathosis in area of injection that could affect anaesthetic assessment. * history of allergy to local anaesthesia. * root resorption affecting more than one third of the root length. * fractured crowns due to trauma. * clinical signs and symptoms of pulp degeneration such as swelling or sinus tracts * radiographic evidence of periapical or interradicular radiolucency * non restorable crowns. * signs of mobility. * ankylosed roots.

Keywords: buffered sodium bicarbonate inferior alveolar nerve block pain pulpotomy articaine
international multicenter, observational, non-interventional prospective study of azilsartan medoxomil in participants with arterial hypertension who are overweight or obese in the russian federation and the republic of kazakhstan

Conditions: Hypertension

Summary: the purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (htn) treatment in the russian federation and in the republic of kazakhstan..

the drug being tested in this study is called azilsartan medoxomil (edarbi®). azilsartan medoxomil is being tested to treat people who have hypertension. this study looks at the clinic systolic and diastolic blood pressure (sbp, dbp) in obese participants who were prescribed azilsartan medoxomil by physicians. the study enrolled 1945 patients. all participants were asked to take azilsartan medoxomil as prescribed by their physician according to local smpc. this multi-center trial was conducted in the russian federation and the republic of kazakhstan. the overall duration of study for observation was approximately 6 months. participants made multiple visits to the clinics as assigned by each physician according to their routine practice, in every 3 months.

Eligibility criteria:
inclusion criteria: 1. male and female participants ≥ 18 years of age with hypertension 1-2 grade. 2. participants with: * newly diagnosed arterial htn or * inadequately controlled previously prescribed monotherapy with renin-angiotensin-aldosterone system (raas) blocker or * inadequately controlled previously prescribed combination therapy with raas blocker + diuretic or raas blocker + calcium antagonist. 3. the physician decides to prescribe edarbi® * as monotherapy or * as a part of combination therapy including diuretics or calcium antagonists; 4. overweight or obesity of any degree (body mass index\> 25 kg/m\^2); 5. is capable of understanding the written informed consent, provides signed and written informed consent, and agrees to comply with protocol requirements. in case the participant is blind or unable to read, informed consent will also be witnessed. exclusion criteria: 1. confirmed secondary htn; 2. contraindications for edarbi® of respective approved local summary of product characteristics (smpc) of edarbi®; 3. any reasons of medical and non-medical character, which in the opinion of the physician can prevent participant participation in the study. 4. is an employee or family member of the investigator or study site personnel. 5. is currently participating in a clinical trial. participation in non-interventional registries is permitted.

Keywords: drug therapy
electronic respiratory sound monitoring system in gastrointestinal endoscopic sedation

Conditions: Gastrointestinal Endoscope; Endoscopic Retrograde Cholangiopancreatogram (ERCP)

Summary: this study aims to evaluate the application of an electronic respiratory sound monitoring system during sedation for gastrointestinal endoscopy and to determine its effectiveness in improving sedation quality. gastrointestinal endoscopy is a common medical procedure, but respiratory complications caused by sedation, such as hypoventilation and airway obstruction, are significant safety concerns. traditional respiratory monitoring methods, such as end-tidal co2 monitoring, are often unreliable due to difficulties in gas sampling during the procedure. in contrast, an electronic respiratory sound monitoring system can accurately capture tracheal breathing sounds and provide important parameters such as respiratory rate and airway obstruction ratio, helping clinicians avoid over-sedation. this study will conduct a randomized controlled trial with 120 participants, divided into a control group with conventional monitoring and an experimental group using the electronic respiratory sound monitoring system. the study will compare sedation dosage, airway complications, and recovery speed between the two groups, and further analyze the clinical value of the system's parameters. the findings of this study will contribute to improving the safety and precision of sedation during gastrointestinal endoscopy and provide evidence for future clinical guidelines.


Eligibility criteria:
inclusion criteria: * patients who undergo routine colonoscopy plus gastroscopy or endoscopic retrograde cholangiopancreatography (ercp) and require deep sedation exclusion criteria: * pregnancy * patients diagnosed with sleep apnea or morbid obesity (bmi greater than 40 kg/m2)

Keywords: electronic repiratory sound monitoring system gstrointestinal endoscopic sedation
internet delivered cbt for body dysmorphic disorder

Conditions: Body Dysmorphic Disorder; BDD

Summary: to evaluate if internet delivered cognitive behavior therapy is an efficacious treatment when compared to a control group consisting of supportive therapy.


Eligibility criteria:
inclusion criteria: * outpatient * ≥ 18 years * primary diagnosis of bdd according to the dsm-5 * bdd-ybocs ≥20 * regular access to a computer with internet access and skills to use the web. exclusion criteria: * psychotropic medication changes within two months prior to the treatment, * completed cbt for bdd within the last 12 months, * other primary axis i diagnosis * current substance dependence * lifetime bipolar disorder or psychosis * suicidal ideation * axis ii diagnosis that could jeopardize treatment participation, * other current psychological treatment that could affect bdd symptoms * a serious medical illness that precludes participation in the study
vault evaluation after icl implantation

Conditions: Nearsightedness

Summary: the purpose of this study is to evaluate the lens vault after implantation of an implantable collamer lens (icl). the icl is designed to be implanted in front of the eye, without removing the natural lens. because of this, it is also known as a phakic iol. the icl has already been approved by the u.s. food and drug administration (fda) to treat mid to high degrees of refractive errors such nearsightedness (also called myopia) with or without astigmatism. once the artificial lens is implanted, a space between the icl and the crystalline lens is created, which is called vault.

the icl will be implanted in both eyes of study subjects. diagnostic instrumentation will be used to measure the vault between the icl and the crystalline lens.

Eligibility criteria:
inclusion criteria: * gender: males and females. * age: 21 to 45 years of age * willing and able to provide written informed consent for participation in the study * willing and able to comply with scheduled visits and other study procedures. * scheduled to undergo icl implantation in both eyes within 1 to 30 days between surgeries. * subjects who require an icl power in the range of -3.00 to -15.00 d. exclusion criteria: * patients who do not qualify for an icl according to the direction for use (dfu) * unstable or worsening myopia * use of any systemic or topical drug known to interfere with visual performance. * irregular astigmatism. * history of retinal detachment. * pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. * pigment dispersion * previous intraocular surgery. * previous refractive surgery. * previous keratoplasty * pupil abnormalities * any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. * participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
enhanced focus in patients with shortness of breath

Conditions: Shortness of Breath; Acute Respiratory Failure

Summary: retrospective observational study performed in a internal medicine ward of a french university hospital. included patients were hospitalized for acute shortness of breath who have benefited from a efocus which was defined as a focused cardiac ultrasound with utilization of doppler measurements. the objectives were the therapeutic and diagnosis changes induced by efocus. the primary endpoint was defined by the pooled introduction or discontinuation of diuretics, antibiotics or anticoagulants associated with efocus results.

it was a retrospective observational study performed in a internal medicine ward of a french university hospital. patients were identified in the hospital database, pertinent features and efocus findings were extracted and anonymized. inclusion criteria: * adult patients admitted to an internal medicine ward from the ed for acute shortness of breath. * realization of an efocus prescribed by the physician in charge of the patient exclusion criteria: • comprehensive echocardiography already performed methods for each identified patient, pertinent data (demography, initial diagnosis and treatment (diuretics, antibiotics, anticoagulants)) and efocus findings were extracted from the hospital files, anonymized and entered in a libreoffice spreadsheet. extracted diagnosis were gathered into the following categories: community-acquired pneumonia (cap), acute cardiogenic pulmonary edema (acpe), pulmonary embolism (pe), chronic obstructive pulmonary disease (copd) and other (other). objectives and endpoints * the main objective was the therapeutic change induced by efocus. the primary endpoint was defined by the pooled introduction or discontinuation of diuretics, antibiotics or anticoagulants associated with efocus results. * the secondary objectives were diagnosis modifications induced by efocus. data analysis * numerical data were presented as mean ± sd or as median with interquartile range depending on the normality. the paired student's t-test was used to compare normally distributed data. the chi-square test was used for the comparison of noncontinuous variables expressed as proportions. a p-value \<0.05 was considered significant. all p-values were two-sided. statistical analysis was realized with r (4.03.3) in the rstudio® environment.

Eligibility criteria:
inclusion criteria: * adult patients admitted to a internal medicine ward from the ed for acute shortness of breath. * realization of an efocus prescribed by the physician in charge of the patient exclusion criteria: * comprehensive echocardiography already performed

Keywords: acute decompensated heart failure pneumonia pulmonary embolism ultrasound